Alcohol use disorder may predispose patients to worse adverse in-hospital outcomes after radical cystectomy and ileal conduit urinary diversion for bladder cancer.
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it recently held a Type B ...
Chugai files regulatory application with MHLF for additional indication of Tecentriq to treat adjuvant therapy for MRD-positive bladder cancer: Tokyo Thursday, January 29, 2026, 0 ...
With 2026 set to be a banner year for M&A as buyers facing patent cliffs compete for a limited pool of late-stage assets ( [3]) , companies demonstrating disciplined pivotal execution and FDA ...
Following discussions with the U.S. FDA, the Agency recommended that the Company submit additional information for its evaluation of this information to potentially support a resubmission of the sBLA ...
Shares of ImmunityBio IBRX surged 17.4% after it announced a recent face-to-face meeting with senior FDA officials to align ...
With $202.3M in cash and an expanded $125M debt facility, ENGN is financially equipped to advance pivotal Cohort 1 and pursue ...
OPDP faulted Altor BioScience for including misleading efficacy claims regarding survival and event avoidance as well as its ...
The 15-day trial centers on Gayle Emerson, a Pennsylvania woman who claimed that her use of Johnson & Johnson's baby powder ...
Shares in ImmunityBio rose sharply after the company said it has agreed a path with the FDA that will allow it to refile for ...
Calfornian immunotherapy company ImmunityBio has announced that it has held a Type B End-of-Phase meeting with the US Food and Drug Administration (FDA) regarding the company’s supplemental Biologics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results